Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18 15:53

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 9 12:10

JAKAS (01167.HK) presented clinical data for a drug treating bone marrow fibrosis in the usa.

JAKS-B (01167.HK) announced that at the 66th American Society of Hematology (ASH) Annual Meeting held in San Diego, California in 2024, preliminary data from the Phase I clinical trial of the BET inhibitor "JAB-8263" for the treatment of myelofibrosis (MF) were presented. The data indicates that "JAB-8263" has good tolerability, with a recommended Phase II dose of 0.3 mg (administered daily). Preliminary efficacy data for the use of "JAB-8263" as a monotherapy for myelofibrosis is encouraging, with most patients experiencing splenic size reduction and a decrease in total symptom scores. JAKS-B revealed.

AASTOCKSDec 9 08:09

JACOS-B (01167.HK) presented initial clinical data on the BET inhibitor JAB-8263 for the treatment of myelofibrosis at the 66th annual conference of hematology in 2024 in the usa.

On December 9, Gelonghui reported that Jianghe Science-B (01167.HK) announced that it showcased preliminary data from a phase I clinical trial of the BET inhibitor JAB-8263 for treating myelofibrosis (MF) at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California, in 2024. The data showed that JAB-8263 has good tolerance, with a recommended dose of 0.3 mg (daily administration) for phase II. The initial efficacy data for JAB-8263 monotherapy for the indication of myelofibrosis is encouraging, with most patients experiencing spleen shrinkage.

Gelonghui FinanceDec 9 07:52

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 16:48

This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?

According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.

Securities TimesNov 26 19:39